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Erratum
Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int J Clin Pract 2006; 60: 967–75.
Following the publication of the above Review article (1), the author would like to apologise for the error made in table 2.
The third column heading should read as follows:
REFERENCE
1 Wright PJ. Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int J Clin Pract 2006; 60: 967–75.
Erratum
Chapple CR, Cardozo L, Steers WD, Govier FE. Solifenacin signiﬁcantly improves all symptoms of overactive bladder
syndrome. Int J Clin Pract 2006; 60: 959–66.
Following the publication of the above Review article, the author would like to apologise for the following:
First error, the previous incorrect text (within section titled ‘Author disclosure’):
Linda Cardozo, MD, FRCOG, receives money for consultancy and/or advisory work, or research or lecturing from the
following companies: Astellas, Lilly/Boehringer Ingelheim, UCB Pharma, Pﬁzer, Gynecare, Plethora and Cook.
Fred E Govier, MD, has nothing to disclose.
The corrected text:
Linda Cardozo, MD, FRCOG, is an advisor/consultant for Astellas, Lilly/Boehringer Ingelheim, UCB Pharma, Pﬁzer,
Gynecare, Plethora and Cook.
Fred E Govier, MD, is an investigator/consultant for Lilly/Icos, Pﬁzer, American Medical Systems, Novartis, Astellas and
Bayer.
Second error, the previous incorrect text [within section titled ‘Introduction’( third paragraph)]:
There is also increasing evidence that acetylcholine may act on receptors in the suburothelial plexus, thereby inﬂuencing the
afferent system and detrusor contraction.
The corrected text:
There is also increasing evidence that acetylcholine may act on receptors expressed by the urothelium, suburothelial nerves or
interstitial cells, thereby inﬂuencing the afferent system and detrusor contraction.
Third error, the previous incorrect text [within section titled ‘Methods, efﬁcacy analysis’( second paragraph)]:
A minimally important difference (MID) was deﬁned as a 15% point change from baseline,
Table 2 Pharmacokinetic parameters of the phosphodiesterase type 5 inhibitors (12,15,19,57–59)
Parameter
Sildenaﬁl
(single 100 mg dose)
Vardenaﬁl
(single 20 mg dose)
Tadalaﬁl
(single 20 mg dose)
Bioavailability (%) 41 15 Undetermined
Maximum plasma concentration (Cmax) (ng/ml) 560 17 378
Change in Cmax with food 29% decrease 20% decrease No change
Time to maximum concentration (Tmax) (h) 0.83 1.0 2.0
Volume of distribution (l) 105 208 63
Protein binding (percentage bound) 96 95 94
Half-life (h) 3.7 3.3–3.9 17.5
Percentage excreted in faeces/urine 80/13 92/5 61/36
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A minimally important difference (MID) was deﬁned as a 5 point change from baseline,
Forth error, in Table 1, please add ‘n (%)’ after the words ‘Male’ and ‘Female’ within the ‘gender’ section.
Gender
Male, n (%) 219 (19) 121 (22) 242 (21)
Female, n (%) 919 (81) 431 (78) 916 (79)
Fifth error, the previous incorrect text (within legend to Figure 4):
MIDs based on Reese et al.
The corrected text:
MIDs based on Kelleher et al., 2004
Sixth error, the previous incorrect text [within section titled ‘Discussion’( 1st paragraph)]:
Therefore, effective treatment of OAB must result in a reduction meaningful to the patient in all of these symptoms.
The corrected text: Therefore, the most efﬁcacious treatment of OAB would ideally result in a reduction meaningful to the
patient in all of these symptoms.
Seventh error, the previous incorrect text [within section titled ‘Discussion’( second paragraph)]:
When using the following deﬁnition of clinical meaning: MID 6 5 percentage point change from baseline;
The corrected text:
When using the following deﬁnition of clinical meaning: MID  5 point change from baseline,
Eighth error, the previous incorrect text (within section titled ‘Acknowledgements’):
The analyses in this paper were funded by an educational grant from Astellas. Editorial assistance was provided by Mark
Rose, Medicus International.
The corrected text:
Whilst the study was sponsored by an educational grant from Astellas, the views and comments expressed here are those felt
appropriate by the authors. Editorial assistance was provided by Mark Rose, Medicus International.
Ninth error, the previous incorrect authors reference 24:
24 Reese PR, Pleil AM, Okano GJ et al.
The corrected authors:
24 Chapple C, Fiala R, Gorilovsky L et al.
Tenth error, the previous incorrect reference 25:
25 Reese PR, Pleil AM, Okano GJ et al. Multinational study of reliability and validity of the King’s Health Questionnaire
in patients with overactive bladder. Quality of Life Research 2003; 12: 427–442.
The corrected reference 25:
25 Kelleher CJ, Pleil AM, Reese PR et al. How much is enough and who says so? The case of the King’s Health Question-
naire and overactive bladder. BJOG 2004; 111: 605–612.
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